Eisai Co., Ltd.
OTC: ESAIY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Haruo Naito
- Employees
- 11,067
- Headquarters
- Tokyo, Japan
- IPO year
- 2023
- Market cap
- $6.8B
- Website
- https://www.eisai.co.jp
Loading ESAIY…
Loading profile data…Frequently asked questions about ESAIY
What does Eisai Co., Ltd. (ESAIY) do?
Eisai Co., Ltd. is a Japanese pharmaceutical firm deeply involved in the entire lifecycle of drug development, from initial research and innovation to manufacturing, distribution, and international trade within Japan. Its comprehensive product portfolio includes prominent medications such as Dayvigo, prescribed for insomnia, and the potent antic...
Where does ESAIY trade?
Eisai Co., Ltd. (ESAIY) trades on the Other OTC.
What sector is ESAIY in?
Eisai Co., Ltd. (ESAIY) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Eisai Co., Ltd.?
Haruo Naito is the chief executive officer of Eisai Co., Ltd. (ESAIY).
Where is Eisai Co., Ltd. headquartered?
Eisai Co., Ltd. is headquartered in Japan.
Does ESAIY pay a dividend?
Yes — Eisai Co., Ltd. (ESAIY) paid a trailing twelve-month dividend of USD 0.23 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did ESAIY go public?
Eisai Co., Ltd. (ESAIY) completed its initial public offering in 2023.
Is ESAIY an ADR?
Yes — ESAIY is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Eisai Co., Ltd. reporting and dividends follow the underlying issuer.